PT - JOURNAL ARTICLE AU - Nurul Azmawati Mohamed AU - Nizam Baharom AU - Wan Shahida Wan Sulaiman AU - Zetti Zainol Rashid AU - Wong Kon Ken AU - Umi Kalsom Ali AU - Siti Norlia Othman AU - Muttaqillah Najihan Samat AU - Najma Kori AU - Petrick Periyasamy AU - Nor Azizan Zakaria AU - Agni Nhirmal Kumar Sugurmar AU - Nur Ezzaty Mohammad Kazmin AU - Cheong Xiong Khee AU - Siti Mariyam Saniman AU - Ilina Isahak TI - EARLY VIRAL CLEARANCE AMONG COVID-19 PATIENTS WHEN GARGLING WITH POVIDONE-IODINE AND ESSENTIAL OILS – A CLINICAL TRIAL AID - 10.1101/2020.09.07.20180448 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.07.20180448 4099 - http://medrxiv.org/content/early/2020/09/09/2020.09.07.20180448.short 4100 - http://medrxiv.org/content/early/2020/09/09/2020.09.07.20180448.full AB - Background Gargling had been reported to have significant roles in the prevention and treatment of respiratory tract infections. The purpose of this study was to assess the ability of regular gargling to eliminate SARS-CoV-2 in the oropharynx and nasopharynx.Methodology This pilot, open labeled, randomized, parallel study compared the effect of 30 seconds, 3 times/day gargling using 1% povidone-iodine (PVP-I), essential oils and tap water on SARS-CoV-2 viral clearance among COVID-19 patients in a tertiary hospital in Kuala Lumpur. Progress was monitored by day 4,6 and 12 PCR (Ct value), gargling and symptoms diary as well as clinical observations.Results Five confirmed Stage 1 COVID-19 patients were recruited for each arm. The age range was from 22 to 56 years old. The majority were males. Two respondents had co-morbidities, which were asthma and obesity. Viral clearance was achieved at day 6 in 100%, 80%, 20% and 0% for 1% PVP-I, essential oils, tap water and control group respectively. Analysis of 1% PVP-I group versus control group showed significant p-value for comparison of PCR results on Day 4, Day 6 and Day 12.Conclusions This preliminary study showed that gargling with 1% PVP-I and essential oils show great potential to be part of the treatment and management of Stage 1 COVID-19. Larger studies are required to ascertain the benefit of gargling for different stages of COVID-19 patients. This study was registered in clinicaltrial.gov (NCT04410159).Competing Interest StatementThe authors have declared no competing interest.Clinical Trialclinicaltrial.gov (NCT04410159)Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04410159?cond=gargle+covid&draw=2&rank=7 Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study received approval from the Research and Ethics Committee, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM PPI/111/8/JEP-2020-372).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request https://clinicaltrials.gov/ct2/show/NCT04410159?cond=gargle+covid&draw=2&rank=7